Molecular and immune pathobiology of human angiosarcoma

Area of Science:

• Oncology
• Cancer Biology
• Immunology

Background:

• Angiosarcoma is a rare, heterogeneous endothelial malignancy with diverse anatomical, etiological, molecular, and immune characteristics.
• Current targeted agents and immunotherapies show modest impact on angiosarcoma outcomes due to its complexity.
• The lack of novel drug targets and predictive biomarkers hinders effective treatment strategies.

Purpose of the Study:

• To review the molecular and immune landscape of angiosarcoma.
• To associate these characteristics with etiology, anatomical sites, prognosis, and therapeutic options.
• To explore promising technologies for future research and application to other rare cancers.

Main Methods:

• Literature review and synthesis of current research on angiosarcoma.
• Analysis of molecular and immune profiling data.
• Discussion of emerging technologies like single-cell spatial 'omics'.

Main Results:

• Angiosarcoma exhibits significant heterogeneity, complicating therapeutic development.
• Current treatments have limited efficacy, underscoring the need for new targets and biomarkers.
• Molecular and immune profiling are crucial for understanding angiosarcoma subtypes.

Conclusions:

• Further characterization of angiosarcoma's molecular and immune profiles is essential.
• Advanced technologies like single-cell spatial 'omics' offer potential for deeper insights.
• Developing targeted therapies and predictive biomarkers remains a critical unmet need for angiosarcoma patients.